Previous Article | Next Article 
Clinical and Diagnostic Laboratory Immunology, July 2000, p. 574-577, Vol. 7, No. 4
1071-412X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Antibody to Heat Shock Protein Can Be Used for Early Serological
Monitoring of Helicobacter pylori Eradication
Treatment
Naoko
Yunoki,1
Kenji
Yokota,2
Motowo
Mizuno,1
Yoshiro
Kawahara,1
Masayasu
Adachi,1
Hiroyuki
Okada,1
Shyunji
Hayashi,3
Yoshikazu
Hirai,3
Keiji
Oguma,2,* and
Takao
Tsuji1
First Department of Internal
Medicine1 and Department of
Bacteriology,2 Okayama University Medical
School, 2-5-1 Shikata-cho Okayama 700-8558, and Department
of Microbiology, Jichi Medical School, 3311-01 Yakushiji
Minami-kouch Tochigi 329-0431,3 Japan
Received 5 November 1999/Returned for modification 8 February
2000/Accepted 7 April 2000
 |
ABSTRACT |
Infection with Helicobacter pylori induces humoral
immune responses against various antigens of the bacterium. Heat shock proteins (hsps) are immunodominant antigens in various diseases including H. pylori infection. In the present study, we
measured the anti-hsp antibody titers in 42 patients with H. pylori-infected peptic ulcers during a bacterial eradication
study. The patients were treated with a proton pump inhibitor and
antimicrobial agents to eradicate the organism. Their sera were
obtained at pretreatment and at 1 month and 6 months after the
eradication therapy. The titers of immunoglobulin G antibodies to the
H. pylori hsp, whole-cell lysate, and urease (30-kDa
subunit) antigens in serum were measured by a capture
enzyme-linked immunosorbent assay. The levels of H. pylori hsp60 antibodies in sera collected 1 month after treatment had declined significantly, even when changes in the titers of antibodies to whole-cell and urease antigens were not apparent. These
results suggest that measurement of antibodies to H. pylori hsp60 in serum is useful for the early monitoring of the
effectiveness of eradication therapy.
 |
INTRODUCTION |
Helicobacter pylori is
associated with gastritis and peptic ulcer disease in humans. H. pylori infection induces the host's constitutional immune
response against various antigens of this bacterium. The detection of
immunoglobulin G (IgG) antibodies to H. pylori is useful for
the diagnosis of infection. Some investigators reported that the titers
of these antibodies declined during therapy for H. pylori
eradication (1, 12, 14, 15, 17, 18). Kosunen (13)
reported that a consistent decrease in the IgG antibody titer within 6 months of antimicrobial therapy reliably indicated the eradication of
H. pylori (13). However, a serological test that
can be used to judge the success of treatment earlier in the follow-up
period has not yet been established. In this study we measured the
titers of IgG antibodies to the heat shock protein (hsp) hsp60, urease,
and whole-cell lysates of H. pylori in sera from patients
with peptic ulcer during antimicrobial treatment of H. pylori and then assessed its usefulness for the monitoring of
eradication therapy.
 |
MATERIALS AND METHODS |
Patients studied.
We investigated 20 subjects with gastric
ulcer (GU) (17 men and 3 women; age range, 35 to 74 years; mean age, 52 years) and 17 subjects with duodenal ulcer (DU) (13 men and 4 women;
age range, 22 to 51 years; mean age, 36.6 years). All patients
underwent gastroduodenoscopy because of gastrointestinal symptoms.
Examinations were performed in the First Department of Internal
Medicine, Okayama University School of Medicine, and its affiliated
hospitals. At the initial diagnostic endoscopy, all patients were
diagnosed as having a peptic ulcer.
Status of H. pylori infection.
H. pylori
infection status was evaluated by bacterial culture, measurement of
urease activity, and histologic analysis. A patient was judged to be
H. pylori positive if culture and/or histologic analysis of
specimens retrieved endoscopically was positive for the organism; a
patient was classified H. pylori negative if culture, the
urease test, and histologic analysis were negative. A weakly positive
urease test was not considered sufficient for the diagnosis of infection.
Antimicrobial therapy.
After informed consent was obtained,
the patients were treated with dual therapy (2-week course of omeprazol
at 40 mg orally twice daily and amoxicillin at 1,500 mg orally twice
daily). At 1 month and 6 months after the treatment, the patients
underwent endoscopic examination, and biopsies were performed to
evaluate the patient's H. pylori infection status. At the
same time, serum samples were taken and were stored at
30°C until
they were assayed.
Preparation of antigen and antibodies.
H. pylori (ATCC
43504) was cultured in brucella broth with 7% horse serum. The cells
were harvested by centrifugation (6,000 × g, 20 min)
and were washed twice with phosphate-buffered saline (PBS; pH 7.4). The
precipitate was resuspended in ice-cold distilled water containing 4 mM
phenylmethylsulfonyl fluoride and was disrupted with a sonicator. The
broken cells were separated by centrifugation (20,000 × g, 30 min), and its supernatant was designated 20S. The 20S
supernatant was further centrifuged at 100,000 × g for 30 min to remove the cytoplasmic membrane fraction, and its supernatant was designated 100S. The 100S supernatant was used as the antigen in a
capture enzyme-linked immunosorbent assay (ELISA).
The 66-kDa (hsp) and 30-kDa (urease
or A subunit) proteins were
separated from the 20S antigen by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and were electroeluted with an Elutrap apparatus (Schleicher & Schuell, Dassel, Germany). The identity of the eluted proteins was checked by N-terminal sequencing (20), and the concentrations were determined by measuring the absorbance at 280 nm.
Rabbits were immunized with the eluted proteins and the 20S antigens in
Freund's incomplete adjuvant to obtain antibodies against hsp, urease,
and whole-cell lysates of H. pylori. Rabbit IgGs were
purified with a DEAE-Sephacel column (Pharmacia, Uppsala, Sweden).
Antigen-capture ELISA for detection of antibodies in serum.
Antibodies against H. pylori-specific proteins in serum were
detected by an antigen-capture ELISA. In brief, 96-well plates (Costar,
Cambridge, Mass.) were coated with rabbit IgG to the hsp (5 µg) or
urease (5 µg) of H. pylori in 100 µl of 0.1 M
carbonate-bicarbonate buffer (pH 9.6) overnight at 4°C. The wells
were washed twice in PBS containing 0.05% Tween 20 (pH 7.4) and were
blocked with PBS containing 10% skim milk (skim milk-PBS). After the
wells were washed they were incubated with 5 µg of soluble antigen
(100S supernatant) per 100 µl for 1 h at room temperature. Wells
for the assay of hsp and urease were incubated with 100 µl of the patient's serum diluted 1:200 in skim milk-PBS. After the wells were
washed they were incubated with peroxidase-conjugated rabbit anti-human
IgG (specific to gamma chains; lot 115; DAKO Inc., Glostrup, Denmark)
and then with o-phenylenediamine (Wako Pure Chemicals,
Tokyo, Japan). Absorbances at 490 nm were measured with a NOVAPATH
microplate reading spectrophotometer (Bio-Rad, Hercules, Calif.).
The patients' levels of antibodies against
H. pylori whole
cells were also obtained by capture ELISA with an anti-
H.
pylori whole-cell antibody. The wells were coated with 1 µg of
anti-whole-cell
IgG to catch various antigens of the bacterium and were
blocked
with skim milk-PBS. The wells were incubated with 100 µl of
the
patient's serum diluted 1:1,000 in skim milk-PBS. Continuous
reactions
were done in the same way as described
above.
Histopathology.
Formalin-fixed and paraffin-embedded biopsy
specimens were stained with hematoxylin-eosin and were examined to
grade the severity of gastritis. All slides with biopsy specimens were
examined by a single pathologist. Gastritis was classified according to
the Sydney System (2, 16), and its activity was graded on a
scale of 0 to 3 as follows, depending on the intensity of neutrophilic infiltration: 0, normal; 1, mild gastritis; 2, moderate gastritis; and
3, highly active gastritis.
Statistical analysis.
Data are expressed means ± standard errors of the means. The titers of IgG antibody to Hsp,
whole-cell lysate, and urease of H. pylori were analyzed
statistically by one-way analysis of variance followed by Scheffe's S
procedure. Pathological parameters were assessed by the Friedman test
and the Dunn procedure and by regression analysis. P values
of <0.05 were considered statistically significant.
 |
RESULTS |
Characterization of antibodies.
Rabbit IgG antibodies against
hsp, urease, and whole-cell lysates were characterized by Western
blotting (Fig. 1). Rabbit sera with
anti-hsp and antiurease antibodies reacted only with the hsp and urease
of the H. pylori 20S antigen, respectively. Sera with
anti-whole-cell antibodies recognized many H. pylori proteins. These sera showed no cross-reactivity with Escherichia coli, Campylobacter jejuni, Campylobacter
fetus, or Campylobacter coli antigens.

View larger version (63K):
[in this window]
[in a new window]
|
FIG. 1.
Western blotting of IgG antibodies to anti-H.
pylori hsp (lane a), urease subunit (lane b), and whole-cell
lysate (lane c).
|
|
Reactivities of patients' sera by capture ELISA.
Capture
ELISAs were assessed by determining the reactivities of serially
diluted sera obtained from three H. pylori-infected patients
or three H. pylori-negative individuals (Fig.
2). According to the dilution curve thus
obtained, we determined that a 1:200 serum dilution should be used for
measurement of titers of antibodies against hsp and urease and that a
serum dilution of 1:1,000 should be used for measurement of titers of
antibodies against whole-cell lysates. The specificities and
sensitivities of three capture ELISAs were calculated for the sera
obtained from the patients pretreatment and the sera obtained from the
patients 6 months after eradication therapy. Cutoff optical densities
(ODs) were determined as the means plus standard deviations for the
sera obtained 6 months after therapy. Cutoff ODs of 0.12, 0.20, and 0.67 were chosen for hsp, urease, and whole cells, respectively. The
capture ELISAs showed high sensitivities but low specificities (Table
1).

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 2.
Dilution curves for sera from three H. pylori-positive patients (open symbol) and three H. pylori-negative individuals (closed symbol).
|
|
Histopathology.
For 14 (70%) of 20 GU patients, the degree of
severity of gastritis was judged to be high. Only 4 (20%) and 2 (10%)
patients had gastritis of grades 2 and 1, respectively.
Histopathological findings for 15 (94%) of 16 of the patients with DUs
were assessed as grade 3 (highly active gastritis) before treatment.
Histological grades (mean ± standard errors) before eradication
therapy were 2.60 ± 0.15 (patients with GU) and 2.94 ± 0.06 (patients with DU). After 1 month of eradication therapy, no patient
had gastritis of grade 3. Histological grades were significantly
decreased in both patients with GUs (1.15 ± 0.08) and patients
with DUs (1.29 ± 0.11). The grades after 6 months of treatment
were 1.15 ± 0.08 (patients with GUs) and 1.23 ± 0.11 (patients with DUs) (Fig. 3). A
regression analysis was conducted for histological grades and antibody
titers. The titers of antibodies to hsp significantly (P = 0.001; R = 0.30) correlated with histological grades;
however, correlations between titers of antibodies to urease
(P = 0.07; R = 0.15), titers of antibodies to
whole cells (P = 0.08; R = 0.23), and histological
grades were not statistically significant.

View larger version (9K):
[in this window]
[in a new window]
|
FIG. 3.
Decline in histological grades (mean ± standard
error) after successful eradication of H. pylori from
patients with GUs (closed circle) and DUs (open circle). *,
P < 0.05; pre, pretreatment.
|
|
Antibody levels.
The antibody levels (means ± standard
errors of the means) for patients with GUs and DUs during treatment are
shown in Fig. 4. Antibody levels were
expressed as absorbances at 490 nm. Anti-hsp antibody levels were
significantly decreased in both GU (P = 0.047) and DU
(P = 0.05) patients 1 month after treatment and
remained decreased in GU (P = 0.031) and DU
(P = 0.005) patients 6 months after treatment. In
contrast, anti-whole-cell and antiurease antibody levels in GU and
DU patients were not significantly decreased 1 month after treatment.
Levels of antibodies to H. pylori whole cells and urease for
both GU patients were significantly decreased at 6 months and were
lower than the levels of antibodies to whole cells at 6 months for DU
patients, but the differences were not significant.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 4.
Antibody levels (mean ± standard error) after
eradication in patients with GUs (closed symbols) and DUs (open
symbols). *, P < 0.05; pre, pretreatment.
|
|
 |
DISCUSSION |
This study has shown that anti-hsp antibody titers were
significantly decreased at an early stage of eradication therapy in patients with either GUs or DUs. On the other hand, it took 6 months
before anti-whole-cell and antiurease antibody titers decreased. Perez-Perez et al. (14) reported that the levels of IgG
antibody to hsp of H. pylori in serum were significantly
higher in infected patients and that the titer was correlated with the
degree of gastric mucosal inflammation. Local IgA levels were
correlated with inflammatory cell infiltration of the gastric mucosa
(8). We previously reported that H. pylori hsp60
was a dominant protein and was mainly induced by heat shock treatment
(20). Furthermore, some reports indicate that hsp60 is
located on the surface of the bacteria (3, 4, 5, 7, 9, 19).
These data indicate that hsp60 develops a tendency to be recognized by
the host and may be closely related to H. pylori-induced inflammation.
The decrease in inflammation in the gastric mucosa of successfully
treated patients showed a correlation with a decrease in the level of
anti-hsp antibodies. Clearly, eradication of H. pylori results in the cure of gastritis and peptic ulcers. However, the relationship between inflammation and mucosal injury is not clear. hsps
were detected in H. pylori-infected human gastric epithelial cells (6). Engstrand and colleagues (7) suggested
that gastric
/
T cells were involved in autoimmunity elicited by
bacterial infection and cross-reacted to autologous hsps from stressed
epithelial cells and that they may play a role in H. pylori-associated gastric epithelial injuries. We recently
reported that hsp60 might be involved with T-cell proliferation in
gastric lymphoid follicles of patients with mucosa-associated lymphoid
tissue (MALT) lymphoma and that antibody to hsp was detected in
patients with MALT lymphoma (10, 11). Transplantation of
lymphocytes from H. pylori-infected MALT lymphoma patients
into severe combined immunodeficient mice induced ulceration in the
stomachs of the mice (21). In several infections and
autoimmune diseases, hsp represents the dominant antigen in the humoral
and cellular immune responses (22). Therefore, characterization of the immune responses to hsp may contribute to the
elucidation of the mechanism of H. pylori-related gastric mucosal injury.
In conclusion, our data suggest that measurement of anti-hsp antibody
levels is useful for the early monitoring of the effectiveness of
H. pylori eradication therapy. Moreover, we postulate that hsp may be involved in the immune reactions responsible for H. pylori-infected gastric mucosal injury.
 |
ACKNOWLEDGMENTS |
This work was supported in part by a grant from the Ministry of
Education, Science, Sport and Culture, Japan and by Otsuka Pharmaceutical Co. Ltd.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Bacteriology, Okayama University, School of Medicine, 2-5-1 Shikata, Okayama 700-8558, Japan. Phone: 81-86-235-7157. Fax: 81-86-235-7162. E-mail: kuma{at}med.okayama-u.ac.jp.
 |
REFERENCES |
| 1.
|
Cutler, A. F., and V. M. Prasad.
1996.
Long-term follow-up of Helicobacter pylori serology after successful eradication.
Am. J. Gastroenterol.
91:85-88[Medline].
|
| 2.
|
Dixon, M. F.,
R. M. Genta,
J. H. Yardly, and P. Correa.
1996.
Classification and grading of gastritis.
Am. J. Sur. Pathol.
20:1161-1181.
|
| 3.
|
Dunn, B. E.,
R. M. D. Roop,
C. C. Sung,
S. A. Sharma,
G. I. Perez-Perez, and M. J. Blaser.
1992.
Identification and purification of a cpn60 heat shock protein homolog from Helicobacter pylori.
Infect. Immun.
60:1946-1951[Abstract/Free Full Text].
|
| 4.
|
Dunn, B. E.
1993.
Pathogenic mechanisms of Helicobacter pylori.
Gastroenterol. Clin. N. Am.
22:43-57[Medline].
|
| 5.
|
Dunn, B. E.,
N. B. Vakil,
B. G. Schneider,
M. M. Miller,
J. B. Zitzer,
T. Peutz, and S. H. Phadnis.
1997.
Localization of Helicobacter pylori urease and heat shock protein in human gastric biopsies.
Infect. Immun.
65:1181-1188[Abstract].
|
| 6.
|
Engstrand, L.,
A. Scheynius,
C. Pahlson,
L. Grimelius,
A. Schwan, and S. Gustavsson.
1989.
Association of Campylobacter pylori with induced expression of class II transplantation antigens on gastric epithelial cells.
Infect. Immun.
57:827-832[Abstract/Free Full Text].
|
| 7.
|
Engstrand, L.,
A. Scheynius, and C. Pahlson.
1991.
An increased number of / T-cells and gastric epithelial cell expression of the groEL stress-protein homologue in Helicobacter pylori-associated chronic gastritis of the antrum.
Am. J. Gastroenterol.
86:976-980[Medline].
|
| 8.
|
Hayashi, S.,
T. Sugiyama,
K. Yokota,
H. Isogai,
E. Isogai,
K. Oguma,
M. Asaka,
N. Fujii, and Y. Hirai.
1998.
Analysis of immunoglobulin A antibodies to Helicobacter pylori in serum and gastric juice in relation to mucosal inflammation.
Clin. Diagn. Lab. Immunol.
5:617-621[Abstract/Free Full Text].
|
| 9.
|
Huesca, M.,
S. Borgia,
P. Hoffman, and C. A. Lingwood.
1996.
Acidic pH changes receptor binding specificity of Helicobacter pylori: a binary adhesion model in which surface heat shock (stress) proteins mediate sulfatide recognition in gastric colonization.
Infect. Immun.
64:2643-2648[Abstract].
|
| 10.
|
Kawahara, Y.,
K. Yokota,
M. Mizuno,
N. Yunoki,
T. Uetsu,
H. Okada,
K. Kobayashi,
Y. Hirai,
K. Oguma, and T. Tsuji.
1999.
Antibodies to human gastric epithelial cell and heat shock protein 60 in Helicobacter pylori positive mucosa associated lymphoid tissue lymphoma.
Gut
45:20-23[Abstract/Free Full Text].
|
| 11.
|
Kobayashi, K.,
K. Yokota,
T. Yoshino,
Y. Kawahara,
A. Dey,
Y. Hirai,
K. Oguma, and T. Akagi.
1998.
Detection of Helicobacter pylori associated antigen and heat shock protein 60 on follicular dendritic cells in the germinal centres of low grade B cell lymphoma of gastric mucosa associated lymphoid tissue (MALT).
J. Clin. Pathol.
51:396-398[Abstract].
|
| 12.
|
Kosunen, T. U.,
K. Seppala,
S. Sarna, and P. Sipponen.
1992.
Diagnostic value of decreasing IgG, IgA, and IgM antibody titres after eradication of Helicobacter pylori.
Lancet
339:893-895[CrossRef][Medline].
|
| 13.
|
Kosunen, T. U.
1995.
Antibody titres in Helicobacter pylori infection: implications in the follow-up of antimicrobial therapy.
Ann. Med.
27:605-607[Medline].
|
| 14.
|
Perez-Perez, G. I.,
W. R. Brown,
T. L. Cover,
B. E. Dunn,
P. Cao, and M. J. Blaser.
1994.
Correlation between serological and mucosal inflammatory responses to Helicobacter pylori.
Clin. Diagn. Lab. Immunol.
1:325-329[Abstract/Free Full Text].
|
| 15.
|
Perez-Perez, G. I.,
A. F. Cutler, and M. J. Blaser.
1997.
Value of serology as a noninvasive method for evaluating the efficacy of treatment of Helicobacter pylori infection.
Clin. Infect. Dis.
25:1038-1043[Medline].
|
| 16.
|
Price, A. B.
1991.
The Sydney System. Histological division.
J. Gastroenterol. Hepatol.
6:209-222[Medline].
|
| 17.
|
Veenendaal, R. A.,
A. S. Pena,
J. L. Meijer,
H. P. Endtz,
M. M. C. van der Est,
W. van Duijn,
F. Eulderink,
J. Kreuning, and C. B. H. W. Lamers.
1991.
Long term serological surveillance after treatment of Helicobacter pylori infection.
Gut
32:1291-1294[Abstract/Free Full Text].
|
| 18.
|
Wang, W. M.,
C. Y. Chen,
C. M. Jan,
L. T. Chen,
D. S. Perng,
S. R. Lin, and C. S. Liu.
1994.
Long-term follow-up and serological study after triple therapy of Helicobacter pylori-associated duodenal ulcer.
Am. J. Gastroenterol.
89:1793-1796[Medline].
|
| 19.
|
Yamaguchi, H.,
T. Osaki,
H. Taguchi,
T. Hanawa,
T. Yamamoto, and S. Kamiya.
1996.
Flow cytometric analysis of the heat shock protein 60 expressed on the cell surface of Helicobacter pylori.
J. Med. Microbiol.
45:270-277[Abstract/Free Full Text].
|
| 20.
|
Yokota, K.,
Y. Hirai,
M. Haque,
S. Hayashi,
H. Isogai,
T. Sugiyama,
E. Nagamachi,
Y. Tsukada,
N. Fujii, and K. Oguma.
1994.
Heat shock protein produced by Helicobacter pylori.
Microbiol. Immunol.
38:403-405[Medline].
|
| 21.
|
Yokota, K.,
K. Kobayashi,
Y. Kawahara,
S. Hayashi,
Y. Hirai,
M. Mizuno,
H. Okada,
T. Akagi,
T. Tsuji, and K. Oguma.
1999.
Gastric ulcers in SCID mice induced by Helicobacter pylori infection after transplanting lymphocytes from patients with gastric lymphoma.
Gastroenterology
117:893-899[CrossRef][Medline].
|
| 22.
|
Zugel, U., and H. E. S. Kaufmann.
1999.
Role of heat shock proteins in protection from and pathogenesis of infectious diseases.
Clin. Microbiol. Rev.
12:19-39[Abstract/Free Full Text].
|
Clinical and Diagnostic Laboratory Immunology, July 2000, p. 574-577, Vol. 7, No. 4
1071-412X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Lin, S.-N., Ayada, K., Zhao, Y., Yokota, K., Takenaka, R., Okada, H., Kan, R., Hayashi, S., Mizuno, M., Hirai, Y., Fujinami, Y., Oguma, K.
(2005). Helicobacter pylori heat-shock protein 60 induces production of the pro-inflammatory cytokine IL8 in monocytic cells. J Med Microbiol
54: 225-233
[Abstract]
[Full Text]
-
Takenaka, R., Yokota, K., Ayada, K., Mizuno, M., Zhao, Y., Fujinami, Y., Lin, S.-N., Toyokawa, T., Okada, H., Shiratori, Y., Oguma, K.
(2004). Helicobacter pylori heat-shock protein 60 induces inflammatory responses through the Toll-like receptor-triggered pathway in cultured human gastric epithelial cells. Microbiology
150: 3913-3922
[Abstract]
[Full Text]
-
Ishii, E., Yokota, K., Sugiyama, T., Fujinaga, Y., Ayada, K., Hokari, I., Hayashi, S., Hirai, Y., Asaka, M., Oguma, K.
(2001). Immunoglobulin G1 Antibody Response to Helicobacter pylori Heat Shock Protein 60 Is Closely Associated with Low-Grade Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. CVI
8: 1056-1059
[Abstract]
[Full Text]